We innovate and advance novel therapies to provide greater choice and freedom to broad patient populations. Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central ...
Brii Biosciences is a biotechnology company developing therapies to improve patients’ health by addressing high unmet medical needs with limited treatment options. The Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. Established in 2018 and led by a visionary and experienced leadership team, Brii Bio now has ...
BRII-179 (VBI-2601) is a novel virus-like particle (VLP)-based therapeutic vaccine intended for the treatment of individuals with chronic HBV infection. It is a new adjuvant formulation and higher dose of the 3-antigen third generation prophylactic HBV vaccine PreHevbri® that contains all three HBV surface envelope proteins (Pre-S1, Pre-S2, and S) (Figure 1).
DURHAM, N.C., and BEIJING, China – – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced top-line results from a Phase 1 study evaluating its long-acting, single-injection therapy ...
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII ...
About BRII-835/BRII-179 Combination BRII-835/BRII-179 is currently in Phase 2 development in China as a combination therapy for HBV functional cure. BRII-835 is a GalNAc-conjugated siRNA targeting all HBV viral RNAs that has shown to block viral transcription, reduce viral protein, and alleviate immune suppression.